Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Lattice Biologics's Sloan Ratio for the quarter that ended in Jun. 2021 was 0.00%.
As of Jun. 2021, Lattice Biologics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Lattice Biologics Sloan Ratio % Historical Data
The historical data trend for Lattice Biologics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lattice Biologics's Sloan Ratio %
For the Medical Devices subindustry, Lattice Biologics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lattice Biologics's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Lattice Biologics's Sloan Ratio % falls into.
Lattice Biologics Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Lattice Biologics's Sloan Ratio for the fiscal year that ended in Sep. 2020 is calculated as
Lattice Biologics's Net Income for the trailing twelve months (TTM) ended in Jun. 2021 was -0.316 (Sep. 2020 ) + -0.345 (Dec. 2020 ) + -0.489 (Mar. 2021 ) + -0.032 (Jun. 2021 ) = C$-1.18 Mil.
Lattice Biologics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2021 was 0.607 (Sep. 2020 ) + -0.188 (Dec. 2020 ) + -0.679 (Mar. 2021 ) + 0.002 (Jun. 2021 ) = C$-0.26 Mil.
Lattice Biologics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2021 was -0.751 (Sep. 2020 ) + 0 (Dec. 2020 ) + 0 (Mar. 2021 ) + 0 (Jun. 2021 ) = C$-0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lattice Biologics (TSXV:LBL.H) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2021, Lattice Biologics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Lattice Biologics Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Lattice Biologics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Lattice Biologics (TSXV:LBL.H) Business Description
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:LBL.H has been successfully added to your 